https://rijournals.com/biological-and-applied-science/

RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 3(3):21-24, 2024

©RIJBAS Publications

Online ISSN: 1115-6171

Print ISSN: 1597-2879

Gene Editing with CRISPR: Ethical and Clinical Implications

Kamanzi Ntakirutimana G.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

CRISPR-Cas9 gene editing has revolutionized genetic research and clinical applications by offering unprecedented precision and potential for treating previously incurable diseases. However, this technology raises significant ethical, legal, and societal concerns, particularly in the context of human clinical trials. This paper examines the ethical dilemmas posed by CRISPR, including inheritable genetic modifications, regulatory challenges, and safety concerns related to off-target effects. It also explores current and future clinical applications, regulatory frameworks, and case studies illustrating the moral complexities of using CRISPR for therapeutic purposes. In conclusion, the responsible development of CRISPR technology must balance innovation with ethical safeguards to protect humanity from unforeseen consequences.

Keywords: CRISPR-Cas9, Gene editing, Ethical implications, Clinical applications, Inheritable genetic modification.

INTRODUCTION

Gene editing in living organisms has moved rapidly from science fiction to reality, driven by breathtaking progress in the innovation and application of CRISPR-Cas9. The potential benefits for healthcare, in enabling therapies for incurable genetic defects and debilitating diseases, are driving significant investment and development activity in this field, with the first clinical trials of CRISPR-Cas9 technology initiated in China and the United States. Such is the pace of progress that it is now time to consider the ethical and governance implications of gene editing in the healthcare space. This chapter discusses the rapid development of CRISPR technology, its application in gene editing and regulation of gene expression, and highlights the most relevant issues - ethical, legal, and societal - relating to clinical translation [1, 2].

ETHICAL CONSIDERATIONS IN GENE EDITING WITH CRISPR

Therapies resulting from the process of gene editing have the potential to be immensely beneficial to modern medical practice. Treatments derived from gene editing can potentially cure or ameliorate significant human health issues such as life-threatening genetic disorders, chronic illness, diseases, and conditions that could harm the fetus during development, enhance fertility, improve single-digit cured cancers, and eliminate mosquito-borne illnesses. The growing use of gene editing in clinical settings, on the other hand, raises a slew of positionally uncomfortable queries for healthcare experts and culture in general. This investigation fundamentally focuses on the moral aspects of using CRISPR gene editing and attempting to discover the appropriate achievable methods or criteria for using CRISPR to manage individuals or comparing human ethics features in the operations when involving CRISPR [3, 4]. Using CRISPR explicitly in humans is a human commitment that must not be underestimated. It necessitates looking at several facets of story and ethics, as well as experts taking on a completely different collection of responsibilities regarding the applications for the benefit of the public. Authorities and humankind must guarantee that enduring ethical principles in the history of medicines are not overlooked by the techniques. Scientists and policymakers have identified ethical concerns and sensitivities related to CRISPR-modified individuals, which include the apprehension of inheritable genetic shift and the necessity for modifications in research strategies. Each of these tenets of healthcare ethics should be taken into account when any attempt to get CRISPR genes is assessed. The thought of conceptus genome

substitute should be rigidly outlined with suitable professional and community recommendations to guarantee that mistakes caused by any usage of genomic editing are thus bred [5, 6].

REGULATORY FRAMEWORKS AND GUIDELINES

On 16 July 2020, the Court of Justice of the European Union (CJEU) performed a courageous act by defining that organisms obtained using mutagenesis do fall under the definition of GMO as provided in Directive 2001/18. The act of authorizing, deregulating, or using such organisms in the environment, for any purpose, should therefore be done according to the regulations and guidelines developed under this directive [7, 8]. It took 10 long years after the first publication of off-target mutation in eukaryotes to show that there are many similarities between the CRISPR-Cas9 systems used to edit genes associated with afforestation and those applied to eukaryotic genomes. However, it is also clear that while the mechanism of activity and the associated potential risk of off-target mutation are practically the same, the diversity and complexity of the genomes to be addressed by these technologies are completely different [9, 10]. The specificity of the genetic changes associated with the CRISPR-Cas9 systems applied for afforestation is less important, and the potential effect of an off-target mutation should mainly be evaluated for the competitive value of the genetically modified trees in their ecological environment. The time required to deregulate the edited trees is another key consideration [11, 12].

CURRENT AND FUTURE CLINICAL APPLICATIONS OF CRISPR

The potential uses for CRISPR/Cas9 continue to expand, reaching beyond the treatment of rare heritable disorders. These related clinical applications introduce additional ethical and safety considerations. CRISPR/Cas9 preclinical and clinical research is ongoing for several indications, including cancer, HIV, Huntington's disease, blindness, and organ transplant tolerance, and there are patents for thousands of potential CRISPR-based treatments, such as for Alzheimer's, diabetes, and autism. This chapter describes advances and issues related to the clinical use of CRISPR/Cas9 on somatic and germline cells, off-targeting, and patient-participant eligibility and consent in clinical studies [13, 14]. High hopes for increasing the diversity of clinical applications for CRISPR/Cas9 have driven the biotechnological research of somatic gene editing, that is, the alteration of only somatic cells, which are not inherited and do not contribute to the germ line. Somatic gene editing has shown scientific advances and potential benefits for very few diseases. Conversely, somatic editing raises serious ethical and safety concerns and raises a general concern about the exclusivity of CRISPR-based treatments. In addition, most somatic CRISPR trials and a couple of human embryos' research have been conducted in countries other than the US, which have lower clinical trial barriers than the multifactorial ones set by the RAC and FDA/NHGRI. In fact, a condition for allowing somatic gene editing is a fail-proof method to rule out the possibility of heritable changes by effectively distinguishing edited from not-edited cells. The proper development of the techniques required to give patients ample access to CRISPR-based treatments, and its use, are grounded to sound ethical foundations that serve the common good [15, 16].

CASE STUDIES AND ETHICAL DILEMMAS IN GENE EDITING

One of the common assumptions is that CRISPR-Cas9 gene-editing technology is a neutral tool that is only as biased or responsible as the people who wield it. Technology is never neutral, and value-laden decisions in science should be well articulated and serve as context for further discussions. This paper examines CRISPR gene-editing technology and weighs the clinical and ethical implications through various case studies and ethical dilemmas related to somatic gene therapy and germline gene therapy. The rest of the paper is organized in the following manner. Firstly, the paper provides a background on genetics and gene-editing techniques. Secondly, a brief introduction to CRISPR technology is provided. Thirdly, we discuss ethical and clinical implications of CRISPR technology [17, 18]. Additional factors, such as trust, legitimacy, effective management, and the social responsibility for handling CRISPR research and its results in an ethically and legally prudent manner, will be discussed. Fourthly and fifthly, we examine novel genomics and germ line gene therapy case studies to illustrate ethically challenging and liable implications. Lastly, a conclusion will be provided. It is important to state that we are less concerned about the methodological and materialistic aspects of CRISPR gene-editing technology and do not wish to interpret it as mere bioengineering. The discussion on CRISPR gene-editing technology presented here highlights bias rooted in both methods and materialisms approach where science, ethics, and human are articulated together [19, 20,21].

CONCLUSION

CRISPR-Cas9 presents transformative possibilities for genetic medicine, offering hope for treating debilitating genetic disorders and advancing biomedical research. However, the ethical and clinical implications of its use necessitate careful consideration and robust regulatory oversight. As the boundaries between treatment and genetic enhancement blur, it becomes crucial to develop clear ethical guidelines that address both the risks and benefits of gene editing. Global governance, public

engagement, and interdisciplinary collaboration will be essential in ensuring that CRISPR technology is applied in a manner that maximizes its therapeutic potential while minimizing harm and safeguarding future generations.

REFERENCES

1. Gostimskaya I. CRISPR–cas9: A history of its discovery and ethical considerations of its use in genome editing. Biochemistry (Moscow). 2022. springer.com
2. Morshedzadeh F, Ghanei M, Lotfi M, Ghasemi M, Ahmadi M, Najari-Hanjani P, Sharif S, Mozaffari-Jovin S, Peymani M, Abbaszadegan MR. An update on the application of CRISPR technology in clinical practice. Molecular Biotechnology. 2024 Feb;66(2):179-97. springer.com
3. van Haasteren J, Li J, Scheideler OJ, Murthy N, Schaffer DV. The delivery challenge: fulfilling the promise of therapeutic genome editing. Nature biotechnology. 2020 Jul;38(7):845-55. [HTML]
4. Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell. 2020. cell.com
5. Kropf M. The ethically significant difference between dual use and slippery slope arguments, in relation to CRISPR-Cas9: philosophical considerations and ethical challenges. Research Ethics. 2024. sagepub.com
6. Piergentili R, Del Rio A, Signore F, Umani Ronchi F, Marinelli E, Zaami S. CRISPR-Cas and its wide-ranging applications: From human genome editing to environmental implications, technical limitations, hazards and bioethical issues. Cells. 2021 Apr 21;10(5):969. mdpi.com
7. Van der Meer P, Angenon G, Bergmans H, Buhk HJ, Callebaut S, Chamon M, Eriksson D, Gheysen G, Harwood W, Hundleby P, Kearns P. The status under EU law of organisms developed through novel genomic techniques. European Journal of Risk Regulation. 2023 Mar;14(1):93-112. cambridge.org
8. Schebesta HA. Confédération paysanne case (C-528/16): legal perspective on the GMO judgment of the European court of justice. Revue européenne de droit de la consommation (REDC). 2020;2020(2):369-78. wur.nl
9. Zheng N, Li L, Wang X. Molecular mechanisms, off-target activities, and clinical potentials of genome editing systems. Clinical and Translational Medicine. 2020. wiley.com
10. Palve V, Liao Y, Rix LLR, Rix U. Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Seminars in cancer biology. 2021. nih.gov
11. Zhao Y, Tian Y, Sun Y, Li Y. The Development of Forest Genetic Breeding and the Application of Genome Selection and CRISPR/Cas9 in Forest Breeding. Forests. 2022. mdpi.com
12. Hao L, Pu X, Song J. Introduction of mutations in plants with prime editing. Methods. 2021. [HTML]
13. Bhattacharjee G, Gohil N, Khambhati K, Mani I, Maurya R, Karapurkar JK, Gohil J, Chu DT, Vu-Thi H, Alzahrani KJ, Show PL. Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. Journal of Controlled Release. 2022 Mar 1;343:703-23. [HTML]
14. Liu W, Li L, Jiang J, Wu M et al. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precision clinical medicine. 2021. oup.com
15. Delhove J, Osenk I, Prichard I, Donnelley M. Public acceptability of gene therapy and gene editing for human use: a systematic review. Human gene therapy. 2020. researchgate.net
16. Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020. nih.gov
17. Xu MM. CCR5-Δ32 biology, gene editing, and warnings for the future of CRISPR-Cas9 as a human and humane gene editing tool. Cell & bioscience. 2020. springer.com
18. Chuang CK, Lin WM. Points of view on the tools for genome/gene editing. International Journal of Molecular Sciences. 2021. mdpi.com
19. Brokowski C, Adli M. Ethical considerations in therapeutic clinical trials involving novel human germline-editing technology. The CRISPR Journal. 2020. researchgate.net
20. Ayanoğlu FB, Elçin AE, Elçin YM. Bioethical issues in genome editing by CRISPR-Cas9 technology. Turkish Journal of Biology. 2020. tubitak.gov.tr
21. Ugwu Okechukwu Paul-Chima, Anyanwu Chinyere Nkemjika, Alum Esther Ugo, Okon Michael Ben, Egba Simeon Ikechukwu, Uti Daniel Ejim and Awafung Emmanuel Adie.CRISPR-Cas9 Mediated Gene Editing for Targeted Cancer Therapy: Mechanisms, Challenges, and Clinical Applications. NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES, 2024. 5(1):97-102. https://doi.org/10.59298/NIJBAS/2024/5.1.9297102

CITE AS: Kamanzi Ntakirutimana G. (2024). Gene Editing with CRISPR: Ethical and Clinical Implications. RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES *3*(*3*):21-24.